Patients with SAH with EVDs (n = 26) were prospectively enrolled for the 12 months after implementation of the EVD mobility algorithm and compared with an age- and sex-matched historical control group
from the 12 months before algorithm adoption (n = 19).
The historical control group
did not receive the HFS experience, as it was not a part of the simulation experience, but the group did receive education and training on all clinical skills used in the HFS experience.
The median survival time for the ADXS-HER2 treated dogs was 956 days, which was significantly longer than the 423 day median survival time of the historical control group
Results were striking, compared with a historical control group
using telaprevir plus pegylated IFN plus ribavirin, with the threshold for noninferiority and superiority set at 43% , and 54%, respectively.
Comparison was made between the patients in this study and two historical control groups
. The first historical control group
, which was treated with oral placebo in this department, comprised 80 patients [66 (82%) males and 18 (18%) females] with hyphema at a mean age of 14.8 [+ or -] 10.7 years old (range=3-58 years old) with the same race and demographic characteristics.